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G. Melissano,* E. Civilini, L. Bertoglio, F. Setacci and R. ChiesaDepartment of Vascular Surgery, Vita-Salute University, Scientific Institute H. San Raffaele, Milan, ItalyIntroduction. The aim of this study was to review our clinical experience with endovascular treatment of aortic arch
aneurysms using different commercially available grafts (Gore, Talent, Endomed, Cook).
Methods. From 1999 to 2004, 97 patients received endovascular treatment for diseases of the thoracic aorta. In 30 cases (26
males, 4 females) the aortic arch was involved.
The left subclavian artery was overstented (Ishimaru zone ‘2’) in 18 cases (60%). Only in the first three cases had the
subclavian artery been revascularized. The left common and subclavian arteries were covered (zone ‘1’) in 6 (20%) cases—all
had the carotid artery reconstructed, either simultaneously (five cases) or as a staged procedure (one case). Finally, the whole
aortic arch was over-stented (zone ‘0’) in 6 (20%) cases, with simultaneous (five cases) or staged (one case) grafting of the
supra-aortic vessels from the ascending aorta.
Results. Perioperative mortality was 2/30 (7%), due to graft migration (zone ‘2’) and intra-operative stroke (zone ‘0’),
respectively. One minor stroke was observed. No cases of paraplegia were recorded. Three type I endoleaks were observed.
Two resolved at 6 months follow-up; one zone ‘0’ graft is still being followed. There was one surgical conversion for endograft
failure 2 weeks after implantation. Thus, the technical success rate was 87% (26/30) cases. The mean follow-up time was
23G17 months. No new onset endoleaks or aneurysm-related deaths were recorded.
Conclusions. Currently available grafts may be deployed in the aortic arch in most instances. De-branching of the aortic
arch with surgical revascularization for zone ‘0’ and ‘1’ seems to be adequate to obtain a satisfactory proximal landing zone.Keywords: Arch aneurysm; Endovascular; Supraortic vessels; Left subclavian artery; Arch de-branching.Introduction
As soon as the endovascular deployment of stent-
grafts was shown to be clinically feasible for the
treatment of aneurysms of the descending thoracic
aorta1,2 it was apparent that the mid thoracic aorta
represented an ‘easy’ area for deployment, whereas
the procedure became more challenging if a short neck
was present at either the distal or proximal landing
zone.
In particular, at the proximal level two anatomical
features posed significant challenges: the curvature of
the aortic arch and the presence of the supra-aortic
vessels. Technological improvements, namely more
flexible sheaths and grafts, nowadays allow deploy-
ment in the arch in most instances. De-branching of theted at the XVIII Annual meeting of ESVS.
ng author. Dr Germano Melissano, MD, IRCCS H. San
artment of Vascular Surgery, Via Olgettina, 60, 20132
: g.melissano@hsr.it
0131 + 08 $35.00/0 q 2004 Elsevier Ltd. All rights reseraortic arch with either intra-thoracic or extra-anatomic
revascularization procedures appears to be the
obvious solution for the second problem.3–7
However, in reality, endovascular treatment of
aneurysms of the aortic arch, especially those that
extend proximally to the origin of the innominate
artery (zone ‘0’),8 is not yet widespread for several
reasons that will be addressed in this paper. The aim of
this study is to review our clinical experience with
endovascular treatment of aortic arch aneurysms and
to describe the new problems encountered treating
more proximal aneurysms and the suggested
solutions.MethodsPatient population
From 1999 to 2004, 97 patients received endovascular
treatment for disease of the thoracic aorta at ourEur J Vasc Endovasc Surg 29, 131–138 (2005)
doi:10.1016/j.ejvs.2004.12.005, available online at http://www.sciencedirect.com onved.
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(proximal neck involving zones ‘0’, ‘1’, and ‘2’).8
This series included 26 males and 4 females with a
mean age of 71G7.9 years (range 56–86 years).
Indications for treatment are listed in Table 1. All
patients were treated electively; no ruptured aneur-
ysm was treated in this series. Since we began
employing this technique only two other patients,
referred with aortic arch aneurysms anatomically
feasible for endovascular treatment, did not receive
an endovascular graft, due to the severity of co-morbid
disease.Table 1. Demographic and clinical data
N8 Sex Age Ø
Zone 0
1 M 71 71
2 M 74 62
3 M 80 59
4 M 72 56
5 M 73 66
6 F 80 68
Zone 1
7 M 74 58
8 M 71 65
9 M 56 58
10 M 69 69
11 M 57 59
12 M 63 65
Zone 2
13 M 77 54
14 F 76 67
15 M 61 59
16 F 69 62
17 M 70 71
18 M 68 59
19 M 77 68
20 M 76 61
21 M 56 –
22 M 77 –
23 M 86 56
24 M 66 39
25 M 67 67
26 F 83 –
27 M 58 55
28 M 78 –
29 M 74 61
30 M 72 51
Abbreviations: penetrating aortic ulcer (PAU); left subclavian revas
subclavian bypass (CCSB); ascending aorta-innominate artery-left comm
(ICS); pre-vertebral ligature of subclavian artery (PLS); first generation
Eur J Vasc Endovasc Surg Vol 29, February 2005Device description
We employed several different types of commercially
available prosthesis which obtained the CE marking:
Gore Excluder TAG (WL Gore and Ass. Flagstaff
AZ): is an expandable polytetrafluoroethylene (ePTFE)
prosthesis supported by self-expanding nitinol stents
with no sutures.9 The original graft also included
longitudinal spines. This graft was withdrawn from
the market in 2001. A modified version of the graft
without the longitudinal spines is now commercially
available in Europe.Etiology Device Stent-graft
size (mm)
Supra-
aortic
trunks
Outcome
ATS Zenith TX1 42!36!
194
AICB OK
ATS Zenith TX1 40!160 AICB OK
ATS TAG (N) 37!150 AICB Stroke-
death
ATS Zenith TX2 34!152C
34!156
AICB Type I EL
ATS Zenith TX1 40!160 AICB OK
ATS Zenith TX2 34!150 AICB Minor
stroke
ATS TAG (O)C
Talent
Ø 37 (6
pieces)
CCSB Type I EL-
OK
ATS Endomed 38!160 CCSB OK
ATS Zenith
Cook TX1
37!150 CCB OK
ATS Zenith
Cook TX1
36!156 CCBCPLS Type I EL-
OK
ATS Zenith
Cook TX1
36!156 CCB OK
ATS TAG (O) 37!150 CCB OK
ATS TAG (O) 34!150 LSR OK
ATS TAG (O) 34!200 LSR OK
ATS TAG (O) 34!150 ICS Conver-
sion
ATS Talent 44!96 LSR OK
ATS Endomed 40!140 ICS Migration-
death
ATS Endomed 38!160 ICS Conver-
sion
ATS Zenith TX1 40!140 PLS OK
ATS Zenith TX1 36!230 ICS OK
Trauma Zenith TX1 38!140 ICS OK
Trauma Zenith TX1 36!106 ICS OK
ATS Zenith TX1 38!100 PLS OK
Saccular Zenith TX1 38!140 ICS OK
Chr Diss Zenith TX1 26!150 PLS OK
PAU Zenith TX1 40!198 ICS OK
Chr Diss TAG (N) 37!150 PLS OK
PAU Zenith TX1 34!156 ICS OK
ATS Zenith TX1 36!156 PLS OK
ATS Zenith TX1 40!139 ICS OK
cularization (LSR); carotid–carotid bypass (CCB); carotid–carotid-
on carotid bypass (AICB); intentional coverage of subclavian artery
Gore stent-graft (TAG O); new Gore stent-graft (TAG N).
Aortic Arch Endografting 133Talent (AVE/Medtronic Inc. Santa Rosa CA): is
composed of polyester graft fabric sutured to nitinol Z-
configured self-expanding stents.10 Deployment is by
manual retraction of the outer sheath of the delivery
system while holding the stent graft in position.
Endofit (Endomed Inc. Phoenix AZ): is constituted
of Nitinol stents blended with e-PTFE fabric, with an
uncovered proximal stent. We used it in the year 2002
with unsatisfactory results.11 Based on early clinical
experience, the company have modified the device.12
This new device however, was not used in this series.
Due to insufficient evidence over the safety of the
device when placed high up in the aortic arch, the
manufacturer amended the Endofit instructions in
January 2004, to restrict use of the device to the
descending thoracic aorta only.13
Zenith TX1 device (William Cook Europe-Denmark):
the endograft consists of self-expandable stainless steel
Gianturcow Z-stents and woven polyester. An uncov-
ered Z-stent with barbs is located at the bottom of the
graft body for fixation. The first proximal covered stent
also has barbs. A new modular device (TX2) that
received CE marking in 2004 and is currently under-
going a trial for FDA approval is now available.Procedures
Graft oversizing 15–20% was based on preoperative
CT scans; aortograpy was performed in all patients.
Mean aneurysm diameter was 61G7 mm. All the
procedures were performed in the operating room,
using a portable digital C-arm image intensifier.
General anaesthesia was the preferred method for
zone 0 and 1 aneurysms, and was used in 21 cases;
epidural anaesthesia was used in eight patients, and
local anaesthesia in one. The contrast agent used was
ioprimide (Ultravist, 300 mg/ml, Berlin, Germany)
and the mean volume given during procedure was
156G58 ml (range 60–370 ml). Cerebrospinal fluid
drainage was not used in this series. The common
femoral artery was used as the access site in 28 cases;
one patient had the device inserted through the
common iliac artery, another one through an infra-
renal aortic tube graft during abdominal open surgery
for combined AAA and thoracic aneurysm repair. All
patients received prophylactic antibiotic therapy peri-
operatively and a bolus of heparin (70 IU/kg).
Zone ‘2’.8 Intentional over-stenting of the left
subclavian artery (LSA) alone was performed in 18
cases. In the first three cases a prophylactic revascu-
larization of the LSA was performed, whereas in the
last 15 cases no additional revascularization procedure
was performed.Zone ‘1’.8 Over-stenting of the origin of the left
common carotid artery was performed in six cases.
Extra-anatomical revascularization was performed as
a staged procedure in one case and as a single
procedure in five cases.
Zone ‘0’.8 Over-stenting of the whole aortic arch was
performed in six cases, in one case as a staged
procedure and as a single procedure in five cases.
Previous revascularization of the brachiocephalic
vessels was performed from the ascending aorta,
through a sternotomy or in one case a mini-
sternotomy.Follow-up
Ranged from 1.2 to 44.3 months (mean 23G17) and
was obtained in all patients. This was achieved with
CT and chest X-ray controls every 6 months for 1 year,
and then yearly.Results
The mean time of fluoroscopy was 29G18 min, with a
mean radiation dose of 93 Gy/cm2. Procedures had a
mean duration of 137G92 min.
In-hospital mortality was 2/30 (7%). One patient
affected by a zone ‘2’8 aneurysm died intra-operatively
1 h after successful endovascular procedure. Post-
mortem examination revealed that the stent graft was
completely kinked within the aneurysm.11,12 No other
case of graft migration was recorded in this series. The
other patient developed an intra-operative stroke after
technically successful treatment of a zone 0 aneurysm
and eventually died on postoperative day 11 (Fig. 1);
one further case of minor stroke was recorded. No
paraplegia was observed in the other patients.
Primary technical success was achieved in 26/30
(87%) patients.14 No procedure was aborted because of
access difficulty, no complications relating to access
vessels were observed. We successfully inserted and
deployed the stent-graft in all cases. Two type I
endoleaks following treatment of a zone 1 aneurysm
were discovered at discharge and both resolved by 6
months follow-up (Fig. 2). One case of type I endoleak
after a zone 0 aneurysm exclusion is still being
followed. In five cases we observed a type II endoleak
from the left subclavian artery (LSA) that resolved
after pre-vertebral ligature of the vessel during the
same procedure.
No patient required immediate conversion to open
repair. We recorded one conversion in a patient with a
zone ‘2’8 aneurysm. Two weeks after a successfulEur J Vasc Endovasc Surg Vol 29, February 2005
Fig. 1. (A) Preoperative angiogram of zone ‘0’ aneurysm. (B)
Revascularization of the brachio-cephalic vessels from the
ascending aorta and exclusion of the aneurysm with new
modified version of Gore TAG graft. In spite of uneventful
deployment of the graft and technical success, this patients
experienced a severe fatal intra-operative stroke and expired
in postoperative day 11.
G. Melissano et al.134deployment of the graft, a routine chest X-ray study
followed by CT scan showed total collapse of the graft
and fracture of three stents that perforated the e-
PTFE.11,12 The patient had no symptoms. Open
surgery for endograft removal and TAA repair was
performed and the postoperative course was
uneventful.
Five patients required packed red blood cells
transfusion, and the mean volume of bleeding during
the procedures was 253G330 ml.
A patient undergoing complete aortic arch grafting
for a zone ‘0’8 aneurysm, experienced a short period ofEur J Vasc Endovasc Surg Vol 29, February 2005asystolic cardiac arrest during surgery.15 The same
patient experienced atrial fibrillation and pulmonary
effusion, respectively, on postoperative day 2 and 3,
which regressed after medical therapy. Another
patient developed postoperative respiratory failure
that required prolonged (20 days) mechanical
ventilation.
Neither peripheral thrombo-embolism nor other
cardiac, renal or other major respiratory problems
were recorded in the remaining patients on the early
postoperative period. In this series (zones 0, 1, 2), LSA
intentional over-stenting without revascularization
was performed in 20 cases with no clinically relevant
adverse consequence.
At follow-up we recorded two late deaths unrelated
to aneurysm repair (7.1%), at 24 and 39 months,
respectively, after the procedure. Freedom from
adverse device-related events was 100%. No cases of
aneurysm sac enlargement were recorded and shrink-
age14 of aneurysm was observed in 15 cases (54%).Discussion
Initially, overstenting of the left subclavian artery
mandated revascularization. However, it is now
generally accepted16–18 that this may not be necessary,
provided that the contralateral vertebral artery and the
branches from which it originates are patent; vertebral
territory stroke after LSA coverage is indeed a
documented risk19 Other reasons that suggest pro-
phylactic revascularization of the LSA are the presence
of a myocardial revascularization with the left internal
thoracic artery, the presence of A-V access shunt for
hemodialysis in left arm, the presence of a lusoria
artery, and the patients being left handed pro-
fessionals.20 Moreover if the thoracic aorta is exten-
sively covered with the endograft, especially with
previous abdominal aortic surgery, prophylactic
revascularization of the LSA may have a role in the
prevention of paraplegia.18
Subclavian-carotid transposition or an extrathoracic
bypass grafting is generally performed to revascular-
ize the LSA.21 Reconstruction of the first or second
segments of the subclavian artery may be complicated
by significant mortality and morbidity rates16,22 and,
to respond to this problem, a variety of endovascular
procedures (scalloped,23 fenestrated24 and branched
stent-grafts25 or in situ fenestration19) are being
investigated. We recorded five cases of type II
endoleak from the left subclavian artery that were
treated intra-operatively by pre-vertebral ligature of
the vessel. As an alternative method, the left
Fig. 2. (A) Postoperative Angio-CT scan showing type I
endoleak (arrows) after deployment of graft (Zenith Cook
TX1) for aneurysm of zone ‘1’. Note over-stenting of the
origin of the left common carotid artery that was grafted to
right carotid artery with ringed ePTFE bypass. (B) Axial scan
view of the endoleak. (C) Axial CT scan taken at the same
level 6 months later showing no endoleaks, expansion of the
stent graft with initial shrinkage of aneurismal sac.
Fig. 3. Kinking of the introducer sheath may jeopardize
release of the endograft (Zenith Cook TX1).
Aortic Arch Endografting 135subclavian artery may be embolized with coils
through a catheter placed in the subclavian artery
from the arm.3
The largest clinical series published to date is that ofKieffer,26 reporting on 16 patients (eight cases of zone
0, eight cases of zone 1 aneurysms) employing a home
made device with mortality, perioperative morbidity
and conversion rates of 25, 62.5 and 12.5%, respect-
ively. Schumacher et al.27 reported more encouraging
results with commercially available endografts in
eight high risk patients affected by an aortic arch
aneurysm: however, one out of three patients with a
zone 0 aneurysm died.
It is clear that the arch is the most challenging area
for endograft deployment. Flexibility of both the
sheath and the graft are crucial for a successful
procedure. Pre-curved grafts are not commercially
available at our institution. Gore grafts are advanced
sheath-less into the arch. The Endofit grafts that we
used were delivered through pre-curved commercial
sheaths. The Cook TX1 sheath is pre-curved, the new
TX2 idrophilic sheath (Flexor) is not pre-curved but it
is so flexible that it advances into the arch without
difficulty.
Our experience with the Talent graft has been
limited mainly for logistic reasons (timely availability
of the product). One of the characteristics of this
widely used product is the high radial force of its
stents, however, this also makes withdrawal of the
sheath very hard or impossible in curved areas.28
Our overall experience with the Endofit graft,
including three cases of arch deployment, have been
reported elsewhere.11,12
The Cook TX1 is suitable for positioning in the arch,
some problems may arise from a tendency to kink of
the introducer sheath. The kinks in the sheath may
prevent deploying in the arch (Fig. 3), if this is the case,Eur J Vasc Endovasc Surg Vol 29, February 2005
Fig. 4. (A) Chest X-ray shows incomplete opening of distal bare stent (Zenith Cook TX1). No endoleak was observed at CT or
aortography (not shown). (B) Ballooning of the stent with a trilobated balloon (Gore WL Gore and Ass. Flagstaff AZ). (C)
Complete opening of the stent after the procedure.
G. Melissano et al.136the device may be pulled back in the descending aorta,
the sheath withdrawn a few centimetres in order to
partially open the first stent and then the device
pushed back in the desired position. The new, more
flexible, introducer sheaths with hydrophilic coating
now available (Flexor) seem to have resolved this
problem. In one of our cases the distal bare stent failed
to open completely at the time of implantation, simple
ballooning was enough to overcome this problem (Fig.
4).
Gore TAG has been available only very recently. Its
flexibility is satisfactory and it is advanced bare to its
final position in the arch. It must be remembered
however, that it opens instantly and a very accurateEur J Vasc Endovasc Surg Vol 29, February 2005positioning is usually not possible. We used it in a
single case of zone ‘0’ landing, and in spite of a
technically very satisfactory and uneventful pro-
cedure, the patient experienced a fatal stroke (Fig. 1).
In our experience the procedure was never a cause
of aortic dissection, however, none of our patients was
treated for acute dissection or intra-mural hematoma.
These are the patients with the most friable aortas and
retrograde dissection into the arch has been described
in some cases, especially when a device with a
proximal bare stent is used.29
So a decade after the introduction of this technique,
we are still awaiting a graft that fulfils the need for
flexibility, precise delivery, reliable fixation and sealing
Aortic Arch Endografting 137and durability essential for deployment in the aortic
arch. In spite of the apparently simple design needed
for the thoracic aorta, unexpected problems arose in
this area, possibly due to the larger diameters, to the
curvature and tortuousity, to the incessant movements
and to the high fatigue loads to which this grafts are
exposed.28 Migration and structural failures turned
out not to be uncommon in this area.30 The approval
process for these devices needs to be rigorous. It is
estimated that more than 21,000 patients are diag-
nosed with thoracic aortic aneurysms each year in the
United States; AAA however, are much more preva-
lent and the effort of corporate companies is consider-
ably greater in this area.
Fenestrated and branched grafts, may in the future
avoid the need for hybrid endovascular procedures.25,
31,32 Currently however, these grafts are in an initial
phase of their development and hybrid procedures
may still be the only alternative to open surgery for the
majority of patients.
In conclusion, currently available materials allow
deploying in the arch in most instances. Surgical
revascularization is needed for cases involving the
right common carotid and the innominate arteries. The
procedure is technically feasible; however, mortality
and morbidity are not negligible.References
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